Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006, 150(2):285-288 | DOI: 10.5507/bp.2006.043
THE RELEVANCE OF BRAIN NATRIURETIC PEPTIDES INVESTIGATION IN VARIOUS CARDIOVASCULAR DISEASES
- a Department of Clinical Biochemistry and Pathobiochemistry, 2nd Medical Faculty, Charles University, Faculty Hospital Motol, Prague, Czech Republic
- b Clinic of Cardiac Surgery, Hospital Homolka, Prague
- c Clinic of Cardiac Surgery, 2nd Medical Faculty, Charles University, Faculty Hospital Motol, Prague
- d Clinic of Internal Medicine, 2nd Medical Faculty, Charles University, Faculty Hospital Motol, Prague
Background: Brain natriuretic peptides are relevant markers of heart impairment.
Aim: We investigated the relevance of investiging brain natriuretic peptides (NT-proBNP, BNP) in monitoring different types of cardiovascular disease (chronic heart failure due to coronary artery disease, cardiomyopathy, acquired valve disease, congenital heart diseases).
Methods: The NT-proBNP assay (Roche) was performed on 280 patients (mean age 49 years; range 20-89 years) and 48 healthy controls (mean age 43 years; range 13-65 years) and BNP assay (Bayer Shionoria) was performed in a subgroup of 42 patients (mean age 50 years; range 20-79 years). Patients were divided into four groups characterized by severity of heart failure according to the New York Heart Association classification.
Results: NT-proBNP concentrations differed in patients with cardiovascular diseases from controls (median 371 ng/l versus 41.5 ng/l, p < 0.0001). The cut off value of NT-proBNP determined in 280 patients with cardiovascular diseases was at 130 ng/l (AUC-area under curve = 0.93; sensitivity 98 %; specificity 79 %). Comparison of NT-proBNP and BNP values in patients showed significant correlation (r = 0.93; p < 0.0001). NT-proBNP showed significant differences between groups.
Conclusions: Measurement of brain natriuretic peptides is useful and relevant in various types of heart diseases including congenital.
Keywords: Brain natriuretic peptides, BNP, NT-proBNP, Cardiovascular diseases, NYHA classification
Received: October 13, 2006; Accepted: November 14, 2006; Published: December 1, 2006 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Gustafsson F, Badskjaer J, Hansen FS, Poulsen AH, Hildebrant P. Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug 2004; 3:1416.
Go to original source...
- Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata K, Fukumoto et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J of Heart Failure 2004; 6:295-0.
Go to original source...
Go to PubMed...
- Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001; 310:1937.
Go to original source...
Go to PubMed...
- Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47:28796.
Go to original source...
Go to PubMed...
- Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NT-proBNP in routine testing and comparison to BNP. Eur J of Heart Failure 2004; 6:289293.
Go to original source...
Go to PubMed...
- Seilhammer JJ, Arfsten A, Miller JA, Lundquist P, Scarborough RM., Lewicki JA, et al. Human and canine gene homologs of porcine brain natriuretic peptide. Biochem Biophys Res Commun 1989; 165(2):6508.
Go to original source...
Go to PubMed...
- Shimizu H, Masuta K, Asada H, Aono K, Sugita K, Sairenji T. Characterization of molecular forms of human pro-brain natriuretic peptide in human plasma. Clin Chim Acta 2002; 334:233239.
Go to original source...
Go to PubMed...
- Mair J, Friedl W, Tomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest 1999; 59:132142.
Go to original source...
- Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AHB et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 2004; 340 (1-2):16372.
Go to original source...
Go to PubMed...
- Kotaska, K, Popelova, J, Tiserova, M, Telekes, P, Vrzanova, M, Bronsky, J et al.: NT-pro BNP and BNP values in cardiac patients with different degrese of left ventricular systolic dysfunction. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.2006; 150 (1):125130.
Go to original source...
- McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J of Heart Failure 2004; 6:26973.
Go to original source...
Go to PubMed...
- Palladini G, Campana C, Klersy C, Baldulini A, Vadacca G, Perfetti V, et al. Serum N-terminal ProBrain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107:24405.
Go to original source...
Go to PubMed...